Fabiflue is a anti-viras tablet Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
Use of fabiflu
Not only does fabiflu ( favipiravir ) of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors Favipiravir has been investigated for the treatment of life-threatening pathogens such as
Ebola virus,
Lassa virus,
Influenza A
Influenza B
now COVID-19
Dose
1-2 tablet / day ( please use only your doctor's advise )
Faviflue tablet price
Rs.103 / tablet
Side effects
- during pregnancy may result in harm to the baby.
- Keep away from children
